Positive results from the Phase 3 TALAPRO-3 trial show that a new combination therapy can significantly delay disease progression in patients with metastatic castration-sensitive prostate cancer who carry HRR gene mutations.
The study evaluated Talazoparib combined with Enzalutamide in patients whose cancer has spread but still responds to hormone therapy. This group represents about 25% of metastatic prostate cancer cases and is known to have DNA repair defects.
The combination therapy significantly improved radiographic progression-free survival, meaning it delayed cancer growth on imaging compared with standard hormone therapy alone. Early data also suggest a strong trend toward improved overall survival.
Benefits were seen across different mutation types, including both BRCA and non-BRCA groups. Patients receiving the combination also had higher response rates, longer-lasting responses, and delayed rises in PSA levels. The safety profile remained consistent with known effects of the two drugs, with no new concerns identified.
These findings are important because patients with these mutations often experience faster disease progression. Moving this combination earlier in treatment may help extend the time patients live without their cancer worsening, potentially changing the standard of care.